GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001049832 | Thyroid | ATC | proteasomal protein catabolic process | 309/6293 | 490/18723 | 1.78e-41 | 1.13e-37 | 309 |
GO:0043161210 | Thyroid | ATC | proteasome-mediated ubiquitin-dependent protein catabolic process | 265/6293 | 412/18723 | 7.09e-38 | 1.49e-34 | 265 |
GO:0009896210 | Thyroid | ATC | positive regulation of catabolic process | 290/6293 | 492/18723 | 2.15e-31 | 1.94e-28 | 290 |
GO:004217635 | Thyroid | ATC | regulation of protein catabolic process | 239/6293 | 391/18723 | 2.63e-29 | 1.85e-26 | 239 |
GO:0045732210 | Thyroid | ATC | positive regulation of protein catabolic process | 148/6293 | 231/18723 | 1.93e-21 | 4.36e-19 | 148 |
GO:014001416 | Thyroid | ATC | mitotic nuclear division | 171/6293 | 287/18723 | 1.13e-19 | 1.66e-17 | 171 |
GO:003304423 | Thyroid | ATC | regulation of chromosome organization | 119/6293 | 187/18723 | 3.55e-17 | 3.40e-15 | 119 |
GO:004477219 | Thyroid | ATC | mitotic cell cycle phase transition | 223/6293 | 424/18723 | 3.46e-16 | 2.88e-14 | 223 |
GO:000007013 | Thyroid | ATC | mitotic sister chromatid segregation | 108/6293 | 168/18723 | 3.53e-16 | 2.90e-14 | 108 |
GO:000734622 | Thyroid | ATC | regulation of mitotic cell cycle | 236/6293 | 457/18723 | 7.58e-16 | 5.92e-14 | 236 |
GO:000081913 | Thyroid | ATC | sister chromatid segregation | 122/6293 | 202/18723 | 4.71e-15 | 3.17e-13 | 122 |
GO:000705913 | Thyroid | ATC | chromosome segregation | 183/6293 | 346/18723 | 8.03e-14 | 4.23e-12 | 183 |
GO:0000209110 | Thyroid | ATC | protein polyubiquitination | 134/6293 | 236/18723 | 1.86e-13 | 9.20e-12 | 134 |
GO:190199015 | Thyroid | ATC | regulation of mitotic cell cycle phase transition | 156/6293 | 299/18723 | 2.19e-11 | 7.80e-10 | 156 |
GO:005198311 | Thyroid | ATC | regulation of chromosome segregation | 60/6293 | 91/18723 | 2.83e-10 | 8.10e-09 | 60 |
GO:009881312 | Thyroid | ATC | nuclear chromosome segregation | 145/6293 | 281/18723 | 3.06e-10 | 8.61e-09 | 145 |
GO:003007111 | Thyroid | ATC | regulation of mitotic metaphase/anaphase transition | 44/6293 | 60/18723 | 3.54e-10 | 9.86e-09 | 44 |
GO:000709111 | Thyroid | ATC | metaphase/anaphase transition of mitotic cell cycle | 45/6293 | 62/18723 | 3.93e-10 | 1.08e-08 | 45 |
GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
GO:004828512 | Thyroid | ATC | organelle fission | 229/6293 | 488/18723 | 4.79e-10 | 1.29e-08 | 229 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HECW2 | SNV | Missense_Mutation | | c.3028N>G | p.Thr1010Ala | p.T1010A | Q9P2P5 | protein_coding | tolerated(1) | benign(0.012) | TCGA-A2-A04R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
HECW2 | SNV | Missense_Mutation | novel | c.3629N>C | p.Gly1210Ala | p.G1210A | Q9P2P5 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-A7-A4SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
HECW2 | SNV | Missense_Mutation | | c.2051N>C | p.Cys684Ser | p.C684S | Q9P2P5 | protein_coding | tolerated_low_confidence(0.8) | benign(0.011) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HECW2 | SNV | Missense_Mutation | | c.1390N>A | p.Asp464Asn | p.D464N | Q9P2P5 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.989) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HECW2 | SNV | Missense_Mutation | | c.403N>A | p.Glu135Lys | p.E135K | Q9P2P5 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HECW2 | SNV | Missense_Mutation | | c.76N>A | p.Glu26Lys | p.E26K | Q9P2P5 | protein_coding | deleterious_low_confidence(0.01) | benign(0.395) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HECW2 | SNV | Missense_Mutation | | c.1270N>A | p.Glu424Lys | p.E424K | Q9P2P5 | protein_coding | deleterious_low_confidence(0.01) | benign(0.028) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HECW2 | SNV | Missense_Mutation | | c.3726G>C | p.Gln1242His | p.Q1242H | Q9P2P5 | protein_coding | deleterious(0.04) | probably_damaging(0.986) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HECW2 | SNV | Missense_Mutation | rs776128886 | c.59N>A | p.Arg20Gln | p.R20Q | Q9P2P5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.978) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
HECW2 | SNV | Missense_Mutation | novel | c.739G>A | p.Glu247Lys | p.E247K | Q9P2P5 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |